Intraday Info: Cara Therapeutics Inc (NASDAQ:CARA) locked on 24/01/2017 at $12.23. It has average volume 996,398 whilst it totals volume 1,265,200. The company has EPS -1.64 and according to analysts next quarter EPS and next year estimate EPS will -0.49 and -1.80 respectively. And it total income 44.80 million.
Ownership Summary: Cara Therapeutics Inc has total institutional ownership 46.10% while its total outstanding shares 27 millions that’s value of holdings $150 million.
Active Positions: In the latest year, CARA 44 holders have raised its positions while it contains total 1,705,755 shares. And the strength of reduced positions holders and held positions holders are 30 and 18 respectively.
New and Sold Out Positions: In CARA force of new positions holders 19 and it has total shares 941,033. And force of sold out positions holders 9 and it has 1,402,114 shares.
Comparison with Other Company: The Market Value of CARA is $333,671 below from AbbVie Inc. market value which is $98M. Current Last Sale of CARA is $12.23 below from ABBV current last sale which is $60.58.
Cara Therapeutics, Inc. is growing product candidates that focus on the body’s peripheral apprehensive machine. Its lead product candidate consists of I.V. CR845, that’s in segment III medical trials for the remedy acute postoperative pain in grownup patients, further to done phase II scientific trials for the remedy of uremic pruritus disease. The business enterprise is also growing Oral CR845, that’s in segment IIa medical trials for the treatment of moderate-to-extreme acute and persistent pain; and CR701, that is in preclinical trial degree for treating neuropathic and inflammatory ache. It has licensing agreements with Chong Kun Dang Pharmaceutical agency to develop, manufacture, and commercialize merchandise containing CR845 in South Korea; and Maruishi Pharmaceutical Co., Ltd to increase, manufacture, and commercialize drug products containing CR845 for acute ache and uremic pruritus in Japan.